At Daiichi Sankyo, we are united by a single purpose, to improve lives around the world through innovative medicines. With a legacy of innovation since 1899, a presence in more than 30 countries, and more than 19,000 employees, we are advancing breakthrough therapies in oncology, cardiovascular disease, rare diseases, and immune disorders. Guided by our 2030 vision to "be an innovative global healthcare company contributing to the sustainable development of society", we are shaping a healthier, more hopeful future for patients, their families, and society.

The position

The Head of Value and Evidence position is responsible for the HTA strategy and the strategic management of RWE's evidence generation for its entire product portfolio in Germany in the areas of Value, Access, and Pricing. This role leads the Health Technology Assessment (AMNOG dossier preparation) as well as Real-World Evidence and Health Economics and Outcomes Research (RWE/HEOR) and ensures that clinical, epidemiological, and health economic evidence is provided early, methodologically sound, and relevant for benefit assessment, price negotiations, and lifecycle management. Furthermore, the position serves as a central interface between medicine, biostatistics, Global HEOR, and Pricing and Reimbursement, and makes a significant contribution to demonstrating patient benefit to the G-BA, IQWiG, and other stakeholders.

Tasks and responsibilities

• Disciplinary and professional management of the Value and Evidence team with the sub-areas HTA/Dossier Preparation and RWE/HEOR
• Resource planning, prioritization and further development of the team structure
• Coaching, goal setting and personal development of team members, as well as ensuring a high-performing, methodologically excellent setup of the department.
• Responsibility for the timely and methodologically sound preparation of the AMNOG dossiers (modules 1–5) in accordance with § 35a SGB V, including the management of external service providers and consultants.
• Development of integrated evidence generation plans across the entire product lifecycle, from the early development phase to post-launch monitoring.
• Management of the conception, implementation and publication of RWE studies, secondary data analyses (including statutory health insurance routine data) and health economic modeling to safeguard benefit assessment and pricing strategy.
• Close coordination with biostatistics, medicine, clinical development and global HEOR functions to ensure the early integration of HTA requirements into study and endpoint designs.
• Professional preparation and support of the consultation procedures with IQWiG and G-BA, as well as support during oral hearings.
• Monitoring of methodological developments (IQWiG methodology paper, G-BA rules of procedure, EU HTA regulation) and derivation of implications for the evidence strategy
• Collaboration with Pricing and Reimbursement to provide evidence-based support for price negotiations and reimbursement amount arguments
• Representation of the Value and Evidence division to management, European and global bodies, and external stakeholders (professional societies, scientific advisory boards, HTA networks)
• Responsibility for budget planning and control of the Value and Evidence area, including external study and consulting budgets.

Education and experience

• Successfully completed university or college degree (Master's preferred) in health economics, business administration, finance, mathematics or a comparable field of study
• 5-8 years of professional experience in HTA, HEOR and/or RWE in a research-based pharmaceutical company, a specialized consultancy or research institution
• Experience in managing employees
• 2-5 years of experience in the design and execution of RWE studies and health economic evaluations, including work with German secondary data sources (e.g., statutory health insurance routine data)
• 2-5 years of proven success in the creation and management of AMNOG dossiers, as well as sound knowledge of IQWiG methodology and G-BA procedural practice, are advantageous.
• 2-5 years of experience working with global HEOR and evidence generation functions in an international corporate environment is an advantage.

Skills and competencies

• Strong leadership skills with experience in managing larger, professionally diverse teams
• High methodological competence in health economics, epidemiology and HTA requirements, coupled with strategic thinking skills
• Confident demeanor and strong communication skills when dealing with scientific committees, authorities and management
• excellent German and English skills
• Ability to prepare complex scientific content in a target-group-oriented manner and translate it into strategic market access decisions.
•